Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial - Wikidata - wikimedia - TriplyDB

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

http://www.wikidata.org/entity/Q36910431

about

Targeted therapy of gastrointestinal stromal tumours Targeting gastrointestinal stromal tumors: the role of regorafenib Molecularly targeted drugs for metastatic colorectal cancer Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives Update on clinical research and state of the art management of patients with advanced sarcomas and GIST Microenvironmental Targets in Sarcoma Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST.Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.A gist of gastrointestinal stromal tumors: A review.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials.Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data.The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.Pancreatic GIST in a Patient with Limited Stage Small Cell Lung Cancer: A Case Report and Review of Published Cases.Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.Drug monographs: bosutinib and regorafenib.Esophageal gastrointestinal stromal tumors presenting as mediastinal mass Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.Recent advances in the treatment of gastrointestinal stromal tumors.Management of gastrointestinal stromal tumors.Regorafenib: carving a niche in the crowded therapeutic landscape.

P2860

62c82b82ea1536d43e15adfed08e6f696c0e8dd2 c7d0bae38963cb74ac668a53b9a53d09317a1055 eb9ae44f48b6ff7ab40fa5365b48b5d6a04ec627

P248

Q26745633-138D5B45-35A9-4E8C-892E-06D9066803C9 Q26747162-2CA7EBEA-CA7B-42C2-B3DB-8D79CF0057F5 Q26828735-8125A056-27CF-4BAF-94CF-01A4A3A9A774 Q27345024-78B98250-131B-49A5-BB88-A0D2649DF971 Q28069560-3D3B386B-2390-48BC-B0F6-12629681F598 Q28073290-B819A9D0-910A-42BF-B729-729430DDD121 Q28081400-6A9A81CE-4D18-4C08-85C6-961C02F8977B Q30593460-FF00309E-738F-48A5-968B-E1F674FC1B30 Q33410655-13FED258-4AD2-49E4-B91D-518A903E4FD6 Q33584090-969DA9E2-65DE-43CB-9B5D-C7E4E0AF6CC6 Q33699635-C99924DA-53C9-45A4-9193-58F2B424E773 Q33807742-C4F11554-FCA0-4B3E-88D6-EFBB3F4A9AFE Q33885957-416D1BEB-95C2-4524-A877-0AA80950F7F6 Q33895608-0D128441-1F81-4345-B946-9FA101216626 Q33944599-AC02070C-9834-4E0D-BE90-94D6854ABD01 Q34387852-74373978-B72B-43B9-B513-085E03BD5DA2 Q34518436-F443AD6D-97FF-4DCA-92ED-F593374070F8 Q34566471-BA30C2F1-B7E7-41DB-81D5-A9D04A57741C Q34645665-F0A810C5-A808-4F9A-B2E2-0598CED46BD3 Q34654203-6A2EA326-50B0-4E54-9A0D-FA779A582631 Q34662946-DD9732BF-0A2B-4AA5-938E-95E85ED82DA5 Q34737119-D9920436-52E9-4DB2-AAD7-064CFD418712 Q34804754-9ACCE193-698F-4BC2-B74B-2CEE4D81D88D Q35434188-CD565339-F3AE-492C-B75A-9C2882280385 Q35519994-6A942225-4F17-4451-A897-E449CDF1F7AA Q35689747-6FBA21C3-AF00-4F46-AC82-113391B37177 Q36078348-07053B64-B21F-4D8F-9CDC-010944C73B1D Q36192000-078B41EA-A5BC-48E1-A1DE-217A78473E67 Q36350526-53FA5FA8-8AC5-4F55-9F58-D815190AD30E Q36509363-E9A46C8E-5028-4E5A-AAE5-45FE77ACF65A Q37192877-585C8276-B919-4CDE-BBBB-1D9D9490BAFA Q37211199-8513109F-1766-43FA-A32F-0A66C99C11D0 Q37220191-068BE761-8016-43FF-96EB-11069FA31045 Q37301465-E8DD2648-3DFD-421E-BF2E-0BE5940B106A Q37340111-2712FF4B-2990-4CB8-9A3A-3DBEA1F2A7DA Q37389277-783CC793-9629-4BC3-8F72-6AF3C9074CF2 Q37429966-9BB17998-3258-410C-9F40-34C3235303D8 Q37704347-3A45250B-DB0E-49FE-A26E-6C626613FF05 Q38081983-4EBD3892-5FDA-4A6D-9D84-9D01AD1E603A Q38096471-0D73F344-973F-45AB-B043-929F4CD0B0DD

P2860

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

http://www.wikidata.org/entity/Q36910431

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Efficacy and safety of regoraf ...... : a multicenter phase II trial

@en

type

label

Efficacy and safety of regoraf ...... : a multicenter phase II trial

@en

prefLabel

Efficacy and safety of regoraf ...... : a multicenter phase II trial

@en

P1433

Q36910431-DFE7A3BC-CCF4-4779-8917-965E74D88385

P1476

Q36910431-30764E4A-C70D-4519-B0AC-1DCF3E4728BC

P2093

Q36910431-0AAF0314-B981-49F2-946D-29BE66AA3AF1

Q36910431-0F57202D-A560-4AA8-95D3-FA4166765296

Q36910431-1AD61F0B-3773-43EE-BB54-C65E3F88E11E

Q36910431-2241B76B-3D98-458E-BF39-984A8781F98F

Q36910431-34985524-DAC8-4ECC-8444-560B72276B56

Q36910431-3E65A817-1050-4FAA-B680-DB1207CEF706

Q36910431-5C899C21-FFD7-4EEA-BDDA-F0E929E52626

Q36910431-5FF9E9E5-ED99-4C1C-B407-2C2A595DC62D

Q36910431-6315A3FB-2E09-4393-BAC5-D4797107B1A7

Q36910431-7F5DAC77-7C76-43E2-9F71-35B971AA1439

P2860

Q36910431-0413D5D5-E78D-4BB0-946D-E5B7E6495837

Q36910431-0D84C9F0-741B-45D8-A999-E7E019E5B1CE

Q36910431-155B6467-038B-4E68-A72D-33B58EA363C9

Q36910431-179016E4-C04E-4FB9-B088-A3ADCF1C1EE5

Q36910431-281D7402-2BB7-43F7-8C5D-46F48309DDE8

Q36910431-409C6461-9B75-470E-96E5-B79FAD705E66

Q36910431-456DC107-870D-4DB9-BA84-085F3EF0D442

Q36910431-4C11D15A-8989-495A-9BEB-4C90E4CB98C5

Q36910431-76B5518D-AEE0-4263-B2C2-5149F9897C68

Q36910431-7B231F41-AFD6-4559-986B-659DEB19125E

P304

Q36910431-FEE1DAA8-9767-41DC-98D0-B1F2E98C104B

P31

Q36910431-B436C707-BF95-461B-875C-634FFAA24BE1

P356

Q36910431-49990337-6D1D-4982-81F8-A41AB04DB9A0

P407

Q36910431-D445BC42-A07D-43B7-92B0-3EBDA87C9CC7

P433

Q36910431-F19B89E6-9A09-4634-917F-4484382C5B80

P478

Q36910431-D2D940A3-73E8-4119-A42C-097CEF57154B

P50

Q36910431-67EEFF17-5167-484F-A01B-E6E1BC798C08

P577

Q36910431-8A9B2278-616B-406A-9289-922C7E760289

P5875

Q36910431-84F2E71C-F466-4079-AA65-2F9F4B1FAA11

P698

Q36910431-81C4978B-CA1D-4292-AADF-8FA69D3A66BB

P921

Q36910431-690E6B25-AFAB-4A98-911E-2F78BA5441CF

Q36910431-AC64B1E1-333C-4607-968D-6440BBEEE6EB

Q36910431-DC0B0CD4-A6D1-49C5-8325-C55232FB6123

P932

Q36910431-37C511E8-70B1-4004-A34C-AA3B1129BA1C

P356

JCO.2011.39.9394

P1433

Journal of Clinical Oncology

P1476

Efficacy and safety of regoraf ...... : a multicenter phase II trial

@en

P2093

Andrew J Wagner

http://www.w3.org/2001/XMLSchema#string

Annick D Van den Abbeele

http://www.w3.org/2001/XMLSchema#string

Christopher L Corless

http://www.w3.org/2001/XMLSchema#string

Edwin Choy

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

James E Butrynski

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Morgan

http://www.w3.org/2001/XMLSchema#string

Jeffrey T Yap

http://www.w3.org/2001/XMLSchema#string

Jonathan A Fletcher

http://www.w3.org/2001/XMLSchema#string

Judith B Manola

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

P304

2401-2407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.39.9394

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Margaret von Mehren

P577

2012-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225054115

http://www.w3.org/2001/XMLSchema#string

P698

22614970

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

multicenter trial

P932

3675695

http://www.w3.org/2001/XMLSchema#string